Quarterly report · Q2
4583.TEDINET S100OXYH
Period2022-01-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥278m | 2022-01-01 → 2022-06-30 | Standalone | Net sales |
| Revenue | ¥713m | 2021-01-01 → 2021-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥385m | 2021-01-01 → 2021-06-30 | Standalone | Net sales |
| Operating income | −¥779m | 2022-01-01 → 2022-06-30 | Standalone | Operating income |
| Operating income | −¥415m | 2021-01-01 → 2021-06-30 | Standalone | Operating income |
| Ordinary income | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2021-01-01 → 2021-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥409m | 2021-01-01 → 2021-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥769m | 2022-01-01 → 2022-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥397m | 2021-01-01 → 2021-06-30 | Standalone | Income before income taxes |
| Net income | −¥771m | 2022-01-01 → 2022-06-30 | Standalone | Profit loss |
| Net income | −¥1.5bn | 2021-01-01 → 2021-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥409m | 2021-01-01 → 2021-06-30 | Standalone | Profit loss |
| Total assets | ¥1.9bn | at 2022-06-30 | Standalone | Assets |
| Total assets | ¥2.3bn | at 2021-12-31 | Standalone | Assets |
| Total assets | ¥3.3bn | at 2021-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥444m | at 2022-06-30 | Standalone | Liabilities |
| Total liabilities | ¥446m | at 2021-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.5bn | at 2022-06-30 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2021-12-31 | Standalone | Net assets |
| Net assets / equity | ¥2.9bn | at 2021-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.5bn | at 2022-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2021-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.5bn | at 2022-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2021-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2021-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.7bn | at 2020-12-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥660m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.1bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥561m | 2021-01-01 → 2021-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥35m | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥341m | 2022-01-01 → 2022-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥271m | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥176m | 2021-01-01 → 2021-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-18.17 | 2022-01-01 → 2022-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.53 | 2022-04-01 → 2022-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.74 | 2021-01-01 → 2021-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-10.16 | 2021-01-01 → 2021-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.16 | 2021-04-01 → 2021-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 75.3% | at 2022-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.4% | at 2021-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.3% | at 2021-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 43,057,600 | at 2022-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 40,781,500 | at 2021-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 40,291,500 | at 2021-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥239m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥691m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥151m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | −¥540m |
| Reconciling Itemsreconciling | segment profit | 2021-01-01 → 2021-06-30 | −¥215m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥103m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥103m |
| jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segment | segment profit | 2021-01-01 → 2021-06-30 | −¥356m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥282m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥282m |
| jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥156m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-01-01 → 2021-06-30 | ¥385m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-01-01 → 2021-06-30 | ¥385m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-01-01 → 2021-06-30 | −¥201m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 436
| Item | Context | Value | Unit |
|---|---|---|---|
| Other noi | CurrentYTDDuration_NonConsolidatedMember | 205000 | JPY |
| Non operating income | Prior1YTDDuration_NonConsolidatedMember | 7165000 | JPY |
| Non operating income | CurrentYTDDuration_NonConsolidatedMember | 16216000 | JPY |
| Interest expenses noe | Prior1YTDDuration_NonConsolidatedMember | 636000 | JPY |
| Interest expenses noe | CurrentYTDDuration_NonConsolidatedMember | 645000 | JPY |
| Stock issuance cost noe | Prior1YTDDuration_NonConsolidatedMember | 586000 | JPY |
| Stock issuance cost noe | CurrentYTDDuration_NonConsolidatedMember | 1416000 | JPY |
| Foreign exchange losses noe | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Foreign exchange losses noe | CurrentYTDDuration_NonConsolidatedMember | 3339000 | JPY |
| Other noe | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Other noe | CurrentYTDDuration_NonConsolidatedMember | 286000 | JPY |
| Non operating expenses | Prior1YTDDuration_NonConsolidatedMember | 1222000 | JPY |
| Non operating expenses | CurrentYTDDuration_NonConsolidatedMember | 5687000 | JPY |
| Ordinary income | Prior1YTDDuration_NonConsolidatedMember | -409402000 | JPY |
| Ordinary income | CurrentYTDDuration_NonConsolidatedMember | -768686000 | JPY |
| Gain on reversal of subscription rights to shares ei | Prior1YTDDuration_NonConsolidatedMember | 12540000 | JPY |
| Gain on reversal of subscription rights to shares ei | CurrentYTDDuration_NonConsolidatedMember | 186000 | JPY |
| Extraordinary income | Prior1YTDDuration_NonConsolidatedMember | 12540000 | JPY |
| Extraordinary income | CurrentYTDDuration_NonConsolidatedMember | 186000 | JPY |
| Income before income taxes | Prior1YTDDuration_NonConsolidatedMember | -396862000 | JPY |
| Income before income taxes | CurrentYTDDuration_NonConsolidatedMember | -768500000 | JPY |
| Income taxes current | Prior1YTDDuration_NonConsolidatedMember | 11874000 | JPY |
| Income taxes current | CurrentYTDDuration_NonConsolidatedMember | 2505000 | JPY |
| Income taxes | Prior1YTDDuration_NonConsolidatedMember | 11874000 | JPY |
| Income taxes | CurrentYTDDuration_NonConsolidatedMember | 2505000 | JPY |
| Profit loss | Prior1YTDDuration_NonConsolidatedMember | -408737000 | JPY |
| Profit loss | CurrentYTDDuration_NonConsolidatedMember | -771005000 | JPY |
| Income before income taxes | Prior1YTDDuration_NonConsolidatedMember | -396862000 | JPY |
| Income before income taxes | CurrentYTDDuration_NonConsolidatedMember | -768500000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration_NonConsolidatedMember | 1478000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration_NonConsolidatedMember | 762000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration_NonConsolidatedMember | 17599000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration_NonConsolidatedMember | -42946000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration_NonConsolidatedMember | -89000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration_NonConsolidatedMember | -6984000 | JPY |
| Decrease increase in advance payments ope cf | Prior1YTDDuration_NonConsolidatedMember | -230054000 | JPY |
| Decrease increase in advance payments ope cf | CurrentYTDDuration_NonConsolidatedMember | 157194000 | JPY |
| Decrease increase in consumption taxes refund receivable ope cf | Prior1YTDDuration_NonConsolidatedMember | -15116000 | JPY |
| Decrease increase in consumption taxes refund receivable ope cf | CurrentYTDDuration_NonConsolidatedMember | 15397000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration_NonConsolidatedMember | -2527000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration_NonConsolidatedMember | 16280000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1YTDDuration_NonConsolidatedMember | 47067000 | JPY |
| Increase decrease in accounts payable other ope cf | CurrentYTDDuration_NonConsolidatedMember | 8985000 | JPY |
| Increase decrease in accrued expenses ope cf | Prior1YTDDuration_NonConsolidatedMember | -15617000 | JPY |
| Increase decrease in accrued expenses ope cf | CurrentYTDDuration_NonConsolidatedMember | -11422000 | JPY |
| Increase decrease in advances received ope cf | Prior1YTDDuration_NonConsolidatedMember | 33577000 | JPY |
| Increase decrease in advances received ope cf | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Increase decrease in contract liabilities ope cf | Prior1YTDDuration_NonConsolidatedMember | － | JPY |
| Increase decrease in contract liabilities ope cf | CurrentYTDDuration_NonConsolidatedMember | -4603000 | JPY |
| Other net ope cf | Prior1YTDDuration_NonConsolidatedMember | -4248000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |